Next generation kinase inhibitors
with unique properties

Potent and selective Nanocyclix leads for known

and novel kinases.

 

New partnering opportunity:  Nanocyclix RIPK2 inhibitors

for use in auto-immune diseases

 

READ MORE

New website

Fully redesigned, Oncodesign's new website will give you access to
exactly what you need in a few clics.

 

 COMING SOON

Translational biomarker approaches
to address patient needs

Pharmaco-imaging in support of therapeutic development

and for drug targeting.

 

 

READ MORE

State-of-the-art models for optimal
predictive value

Patient-derived xenografts and human immune system

models to allow better decisions.

 

 

READ MORE

We partner to advance cancer
research

Creative partnerships to drive development for oncology

and other serious illnesses with no known effective treatment.

 

READ MORE

September 19, 2017
First-half 2017 results
READ MORE
August 31, 2017
Oncodesign announces the acquisition of Bertin Pharma’s pharmaceutical and biotech services businesses
READ MORE

ONCOLOGY TRANSLATIONAL

EXPERIMENTATION

A large panel of technological and scientific solutions for pharmacological qualification of your compounds : a unique oncology preclinical CRO

DISCOVERY PARTNERING

 

A platform-based approach for the discovery of novel chemical entities with therapeutic and diagnostic potential